Daily Respiratory Research Analysis
Analyzed 222 papers and selected 3 impactful papers.
Summary
A large multicenter RCT showed that ciprofol reduces hypoxia versus propofol during gastrointestinal endoscopy in overweight patients. An observational cohort from MIMIC-IV found that ventilatory mechanical power independently predicts short-term mortality in ARDS. A decade-long hospital cohort reported that adults hospitalized with RSV require more respiratory support and resources than influenza, despite similar 30‑day mortality.
Research Themes
- Sedation safety and prevention of procedure-related hypoxia
- Ventilator-induced lung injury and prognostic ventilatory biomarkers
- Comparative outcomes of RSV versus influenza in adult hospitalizations
Selected Articles
1. Ciprofol Versus Propofol for the Prevention of Hypoxia During Gastrointestinal Endoscopy Procedures in Overweight Patients: A Multicenter, Randomized, Controlled Trial.
In a five-center randomized trial (N=1,018), ciprofol sedation reduced the overall incidence of hypoxia and severe hypoxia compared with propofol during GI endoscopy in overweight adults. Secondary outcomes, including subclinical respiratory depression and injection pain, also favored ciprofol without compromising endoscopy success.
Impact: This large multicenter RCT directly addresses procedural hypoxia—a common and clinically important respiratory complication—showing a safer sedation option for overweight patients.
Clinical Implications: For overweight patients undergoing GI endoscopy, ciprofol may be preferred over propofol to reduce hypoxia risk, potentially improving safety in endoscopy suites and reducing rescue interventions.
Key Findings
- Ciprofol significantly reduced the combined incidence of hypoxia and severe hypoxia compared with propofol.
- Subclinical respiratory depression and injection pain were lower with ciprofol, with no reduction in endoscopy success.
- Benefits were demonstrated in a large, multicenter, randomized controlled setting (N=1,018).
Methodological Strengths
- Multicenter, randomized controlled design with large sample size
- Pre-registered trial (NCT05518929) with clearly defined respiratory endpoints
Limitations
- Conducted in overweight patients in Chinese hospitals; generalizability to other populations/settings requires confirmation
- Incomplete abstracted numeric details on absolute hypoxia rates and sedation depth standardization
Future Directions: Head-to-head comparisons across BMI strata and procedural types, with standardized sedation depth and airway management protocols, and evaluation in high-risk cohorts (e.g., OSA) are warranted.
BACKGROUND AND AIMS: To compare the incidence of hypoxia and other sedation-related adverse events (AEs) in overweight patients undergoing gastrointestinal (GI) endoscopy who were sedated using ciprofol or propofol. METHODS: A randomized, controlled trial was conducted in five hospitals in China between September 2022 and August 2023. Patients were randomized into either ciprofol or propofol sedation. The primary outcome was the total incidence of hypoxia and severe hypoxia. The secondary outcomes were hypoxia incidence, severe hypoxia incidence, subclinical respiratory depression incidence, endoscopy success rate, injection pain incidence, and corrective hypoxic measures proportion. RESULTS: A total of 1018 patients were randomized into either ciprofol group (n = 506) or propofol group (n = 512). The mean BMI was 26.23 kg/m CONCLUSIONS: During GI endoscopy, overweight patients are significantly less prone to hypoxia when sedated with ciprofol than with propofol, offering a safer alternative. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05518929).
2. Mechanical power and short-term mortality in critically ill patients with ARDS on mechanical ventilation: Insights from the MIMIC-IV database.
In 1,878 ventilated ARDS patients, higher mechanical power was independently associated with increased in-hospital, 28‑day, and 90‑day mortality, with the highest quartile showing a 32% higher adjusted risk versus the lowest. Mechanical power outperformed traditional predictors in ROC analyses and showed linear risk relationships.
Impact: It validates mechanical power as an integrated prognostic biomarker in ARDS using robust adjustments and multiple performance checks, informing ventilatory strategy assessment beyond single-parameter targets.
Clinical Implications: Mechanical power could be incorporated into ventilation monitoring dashboards to risk-stratify ARDS patients and to guide refinements of lung-protective strategies alongside tidal volume, driving pressure, and PEEP.
Key Findings
- Mechanical power quartiles were independently associated with in-hospital, 28-day, and 90-day mortality; Q4 vs Q1 HR 1.32 (95% CI 1.06–1.64).
- ROC analyses showed mechanical power outperformed traditional predictors with good calibration.
- Restricted cubic spline analysis showed no curvature, supporting a linear risk relationship.
Methodological Strengths
- Large, well-characterized ICU cohort with comprehensive covariate adjustment
- Multiple validation steps (ROC, calibration, RCS, subgroup and sensitivity analyses)
Limitations
- Retrospective single-database design limits causal inference
- Mechanical power not randomized; residual confounding and practice variability possible
Future Directions: Prospective interventional studies should test MP-informed ventilator adjustments and evaluate whether lowering MP independently improves outcomes beyond standard lung-protective settings.
Mechanical power (MP), or an integrated measure of ventilatory stress, has been proposed as an important determinant of ventilator-induced lung injury and clinical outcomes. However, its prognostic significance in patients with acute respiratory distress syndrome (ARDS) remains incompletely understood. We selected adult patients with Berlin ARDS from MIMIC-IV v3.1. Cox proportional hazard regression models were built to explore the relationship between MP quartiles and in-hospital, 28-day, and 90-day mortality, with progressive adjustment for demographics, severity scores, and ventilatory parameters. We also explored model discrimination and calibration, conducted comparative receiver-operating characteristic curves (ROC) and restricted cubic spline (RCS) analyses, and performed Kaplan-Meier, subgroup, and sensitivity analyses as complementary assessments. A total of 1878 patients were included. Each increase in MP was significantly associated with higher in-hospital, 28-, and 90-day mortality. Using full models, Q4 had significantly higher risk than Q1 (HR 1.32; 95% CI 1.06-1.64). MP had stable discriminative performance with good calibration. Using ROC, MP had significantly better performance than traditional predictors. Models built with RCS showed no evidence for curvature. Survival analysis showed successively decreased probabilities with increasing quarters from Q1 to Q4. Sensitivity analyses were largely consistent, with subgroup analyses supporting findings. In patients with ARDS, elevated MP was independently associated with in-hospital, 28-day, and 90-day mortality. These findings suggest that MP may serve as an integrated prognostic marker of ventilatory load rather than a standalone target. Our results warrant further prospective research to determine whether incorporating MP into lung-protective strategies can improve clinical outcomes.
3. A comparison of clinical characteristics and mortality in hospitalised patients with respiratory syncytial virus and influenza virus infections: a cohort study.
Among 2,868 adults hospitalized with PCR-confirmed infection, RSV cases were older with more comorbidities and needed more respiratory support, higher-level care, and had longer stays and readmissions, yet adjusted 30-day mortality was similar to influenza. Fever was more frequent in influenza, whereas wheeze and radiographic infiltrates were more common in RSV.
Impact: This 10-year cohort quantifies the inpatient burden of RSV versus influenza, informing resource allocation and clinical vigilance as adult RSV circulation and testing increase.
Clinical Implications: Hospitals should anticipate higher respiratory support and care intensity for RSV admissions despite similar short-term mortality, and consider triage pathways and prevention strategies (e.g., vaccination/monoclonals in high-risk groups).
Key Findings
- RSV inpatients were older, had more comorbidities, and more often required respiratory support and higher-level care.
- RSV admissions had longer hospital stays and higher readmission rates than influenza.
- Adjusted 30-day all-cause mortality did not differ between RSV and influenza (aOR 0.93; 95% CI 0.64–1.33).
Methodological Strengths
- Large, decade-long cohort with PCR-confirmed pathogens
- Adjusted analyses (logistic regression) for 30-day mortality
Limitations
- Single-center retrospective design may limit external generalizability
- Changes in testing practices and therapeutics over 2012–2021 may confound comparisons
Future Directions: Prospective multicenter studies should evaluate standardized care pathways, predictors of escalation, and the impact of adult RSV vaccines or monoclonal prophylaxis on hospitalization metrics.
OBJECTIVES: RSV infections remain less well described than influenza infections. We compared symptoms, clinical characteristics and mortality in patients admitted with acute respiratory tract infections due to RSV and influenza virus. METHODS: We retrospectively collected data from the medical records of adult patients admitted to Akershus University Hospital with a positive PCR for RSV and influenza virus (H3N2, H1N1, and influenza B) from January 1, 2012 to December 31, 2021. We compared demographics, symptoms, and clinical characteristics, and assessed 30-day all-cause mortality using the Kaplan-Meier estimator and logistic regression. RESULTS: We included 2084 (72.7%) patients with influenza and 784 (27.3%) with RSV. RSV patients were older and more comorbid. Sputum production and dyspnoea were more frequently reported by RSV patients, whereas myalgia, headache, fever, sore throat, and gastrointestinal symptoms were more frequently reported by influenza patients. Fever on admission was more common in patients with influenza, whereas RSV patients more often presented with wheezing, higher white blood cell count, and more radiographic evidence of infection. RSV patients were more likely to require respiratory support, admission to higher levels of care, had longer hospital stays, and higher readmission rates. We observed no significant difference in 30-day mortality (adjusted odds ratio 0.93, 95% CI 0.64-1.33). CONCLUSIONS: RSV and influenza are mostly clinically indistinguishable on admission, but fever is more frequent in influenza patients. RSV is associated with high utilisation of health care resources and a mortality risk comparable to influenza, highlighting the need for increased awareness and knowledge of RSV.